Richard F Pollock - JoVE Visualize

Showing results (71-80 of 86) with videos related to

Pageof 9

Sort By:

Patient Related Outcome Measures|March 28, 2020

Impact of Stigma on People Living with Chronic Hepatitis BJayne Smith-Palmer, Karin Cerri, Urbano Sbarigia, et al.

Diabetes Technology & Therapeutics|September 19, 2025

Improving Time-in-Range in Type 1 Diabetes: Projecting the Clinical and Cost Implications of Automated Insulin DeliverySufyan Hussain, Asli Zeynep Ozdemir Saltik, Jessica J Yu, et al.

Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|October 16, 2024

Association of adverse events and quality of life in patients with unresectable hepatocellular carcinomaIon Agirrezabal, Richard F Pollock, Phuong Lien Carion, et al.

Advances in Therapy|December 5, 2025

Cost-Utility Analysis of Subcutaneous Methotrexate in the Treatment of Patients with Rheumatoid Arthritis in the UKMatthew Tucker, Johannes Pöhlmann, Kristin Grabe-Heyne, et al.

Diabetes Technology & Therapeutics|July 1, 2026

Budget Impact of Advanced Insulin Delivery Systems for the Management of Type 1 DiabetesDanila Fava, Asli Zeynep Ozdemir Saltik, Richard F Pollock, et al.

Diabetes Technology & Therapeutics|October 6, 2023

A European Cost-Utility Analysis of the MiniMed™ 780G Advanced Hybrid Closed-Loop System Versus Intermittently Scanned Continuous Glucose Monitoring with Multiple Daily Insulin Injections in People Living with Type 1 DiabetesJohan Jendle, Maria Ida Buompensiere, Asli Zeynep Ozdemir Saltik, et al.

Diabetes, Obesity & Metabolism|March 30, 2019

Short-term cost-utility of degludec versus glargine U100 for patients with type 2 diabetes at high risk of hypoglycaemia and cardiovascular events: A Canadian setting (DEVOTE 9)Richard F Pollock, Simon Heller, Thomas R Pieber, et al.

Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|May 2, 2018

DEVOTE 5: Evaluating the Short-Term Cost-Utility of Insulin Degludec Versus Insulin Glargine U100 in Basal-Bolus Regimens for Type 2 Diabetes in the UKRichard F Pollock, William J Valentine, Steven P Marso, et al.

Journal of Medical Economics|September 14, 2024

Real-time continuous glucose monitoring vs. self-monitoring of blood glucose: cost-utility in South Korean type 2 diabetes patients on intensive insulinJi Yoon Kim, Sabrina Ilham, Hamza Alshannaq, et al.

Journal of Diabetes Science and Technology|October 22, 2025

Cost-Effectiveness Analysis of Real-Time Continuous Glucose Monitoring Versus Self-Monitoring of Blood Glucose in People With Type 2 Diabetes Treated With Non-Intensive Insulin Therapy in South KoreaJi Yoon Kim, Sabrina Ilham, Hamza Alshannaq, et al.

Pageof 9

Showing results (71-80 of 86) with videos related to

Sort By:

Pageof 9

Patient Related Outcome Measures|March 28, 2020

Impact of Stigma on People Living with Chronic Hepatitis BJayne Smith-Palmer, Karin Cerri, Urbano Sbarigia, et al.

Diabetes Technology & Therapeutics|September 19, 2025

Improving Time-in-Range in Type 1 Diabetes: Projecting the Clinical and Cost Implications of Automated Insulin DeliverySufyan Hussain, Asli Zeynep Ozdemir Saltik, Jessica J Yu, et al.

Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|October 16, 2024

Association of adverse events and quality of life in patients with unresectable hepatocellular carcinomaIon Agirrezabal, Richard F Pollock, Phuong Lien Carion, et al.

Advances in Therapy|December 5, 2025

Cost-Utility Analysis of Subcutaneous Methotrexate in the Treatment of Patients with Rheumatoid Arthritis in the UKMatthew Tucker, Johannes Pöhlmann, Kristin Grabe-Heyne, et al.

Diabetes Technology & Therapeutics|July 1, 2026

Budget Impact of Advanced Insulin Delivery Systems for the Management of Type 1 DiabetesDanila Fava, Asli Zeynep Ozdemir Saltik, Richard F Pollock, et al.

Diabetes Technology & Therapeutics|October 6, 2023

A European Cost-Utility Analysis of the MiniMed™ 780G Advanced Hybrid Closed-Loop System Versus Intermittently Scanned Continuous Glucose Monitoring with Multiple Daily Insulin Injections in People Living with Type 1 DiabetesJohan Jendle, Maria Ida Buompensiere, Asli Zeynep Ozdemir Saltik, et al.

Diabetes, Obesity & Metabolism|March 30, 2019

Short-term cost-utility of degludec versus glargine U100 for patients with type 2 diabetes at high risk of hypoglycaemia and cardiovascular events: A Canadian setting (DEVOTE 9)Richard F Pollock, Simon Heller, Thomas R Pieber, et al.

Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|May 2, 2018

DEVOTE 5: Evaluating the Short-Term Cost-Utility of Insulin Degludec Versus Insulin Glargine U100 in Basal-Bolus Regimens for Type 2 Diabetes in the UKRichard F Pollock, William J Valentine, Steven P Marso, et al.

Journal of Medical Economics|September 14, 2024

Real-time continuous glucose monitoring vs. self-monitoring of blood glucose: cost-utility in South Korean type 2 diabetes patients on intensive insulinJi Yoon Kim, Sabrina Ilham, Hamza Alshannaq, et al.

Journal of Diabetes Science and Technology|October 22, 2025

Cost-Effectiveness Analysis of Real-Time Continuous Glucose Monitoring Versus Self-Monitoring of Blood Glucose in People With Type 2 Diabetes Treated With Non-Intensive Insulin Therapy in South KoreaJi Yoon Kim, Sabrina Ilham, Hamza Alshannaq, et al.

Pageof 9